Papapoulos S E
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Leiden, The Netherlands.
Int J Clin Pract. 2003 Jun;57(5):417-22.
Osteoporosis is a serious, common skeletal disease. Oral bisphosphonates are among the most effective therapeutics available to manage this condition. Currently, bisphosphonates are administered orally either daily or once weekly. Less frequent dosing, while retaining efficacy, may provide greater convenience, thereby promoting long-term adherence to treatment and maximising therapeutic outcomes. Ibandronate is a highly potent nitrogen-containing bisphosphonate that has been given orally or intravenously at variable dosing intervals for the prevention and treatment of osteoporosis. Recent studies with oral ibandronate, given daily or intermittently with a between-dose interval longer than two months to women with postmenopausal osteoporosis, demonstrated significant and sustained antifracture efficacy. Additional studies showed that ibandronate given as a convenient intravenous injection every three months induces significant increases in bone mineral density and suppression of bone turnover. Ongoing studies aim to determine the optimal therapeutic regimen of this promising new bisphosphonate in clinical practice.
骨质疏松症是一种严重的常见骨骼疾病。口服双膦酸盐是治疗这种病症最有效的疗法之一。目前，双膦酸盐的给药方式为每日口服或每周口服一次。给药频率较低，在保持疗效的同时，可能会带来更大的便利，从而促进长期坚持治疗并使治疗效果最大化。伊班膦酸钠是一种高效的含氮双膦酸盐，已以不同的给药间隔通过口服或静脉注射用于预防和治疗骨质疏松症。最近针对绝经后骨质疏松症女性进行的研究，每日或间歇给予口服伊班膦酸钠，给药间隔超过两个月，结果显示出显著且持续的抗骨折疗效。其他研究表明，每三个月进行一次方便的静脉注射给予伊班膦酸钠可显著提高骨密度并抑制骨转换。正在进行的研究旨在确定这种有前景的新型双膦酸盐在临床实践中的最佳治疗方案。
